MRC1 and central nervous system cancer: The results show a significant reduction in the percentage of CD68 (Fig. 7a) and CD206 (Fig. 7b) (a marker of M2 protumoral macrophages [31]) positive cells, in SVZ-vIII tumors treated with VP3.15, but not in GL261 gliomas (Fig. 7c and d).